| Literature DB >> 29734790 |
Pinelopi Vlachou1, Géraldine Le Goff2, Carolina Alonso3, Pedro A Álvarez4, Jean-François Gallard5, Nikolas Fokialakis6, Jamal Ouazzani7.
Abstract
Isolation of marine compounds from living invertebrates represents a major challenge for sustainable and environmentally friendly exploitation of marine bio-resources. To develop innovative technology to trap invertebrate compounds in the open sea, the proof of concept of a system combining external continuous circulation of water with XAD-amberlite solid-phase extraction was validated in an aquarium. In this work, we reported the elicitation of guanidine alkaloid production of Crambe crambe in the presence of Anemonia sulcata, both collected from the Mediterranean Sea. Besides the previously reported crambescidin 359 (1), and crambescidin acid (2), three new compounds were isolated; one carboxylated analog of 1 named crambescidin 401 (3), and two analogs of crambescin B, crambescin B 281 (4) and crambescin B 253 (5). Based on these results, a technology named Somartex® for “Self Operating MARine Trapping Extractor” was patented and built to transfer the concept from closed aquarium systems to open marine ecosystems.Entities:
Keywords: Crambe crambe; Somartex; crambescidins and crambescins; guanidine alkaloids; solid-phase extraction
Mesh:
Substances:
Year: 2018 PMID: 29734790 PMCID: PMC5983283 DOI: 10.3390/md16050152
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Design and pictures of the experimental assembly.
Figure 2HPLC analysis of the MeOH extract of aquarium 4 (Aq-4) under LSD detection.
Figure 3Structures of the isolated compounds 1 to 5.
1H NMR (600 MHz, cryoprobe) and 13C NMR (150 MHz) data for crambescidin acid (2) and crambescidin 401 (3) in CD3OD.
| Crambescidin Acid (2) | Crambescidin 401 (3) | |||||
|---|---|---|---|---|---|---|
| position | δC, type | δH, mult, | HMBC | δC, type | δH, mult, | HMBC |
| 1 | 10.7, CH3 | 0.80; t (7.3) | 2, 3 | 10.9, CH3 | 0.88; t (7.4) | 2, 3 |
| 2 | 30.8, CH2 | 1.54, m; 1.47, m | - | 30.2, CH2 | 1.54, m; 1.46, m | - |
| 3 | 72.2, CH | 4.34, br m | - | 72.2, CH | 4.56, br m | - |
| 4 | 134.5, CH | 5.51, br d (11.2) | 2, 3, 6 | 134.3, CH | 5.54, br d (11.1) | 3, 6 |
| 5 | 131.7, CH | 5.72, br m | 3, 6, 7 | 131.4, CH | 5.76, br m | 3, 6, 7 |
| 6 | 24.6, CH2 | 2.15, m; 2.43, m | 4, 5, 7, 8 | 24.5, CH2 | 2.15, m; 2.43, m | 4, 5, 7, 8 |
| 7 | 37.4, CH2 | 2.02, m; 2.24 m | 5, 6, 8, 9 | 37.8, CH2 | 2.02, m; 2.61 br t (13.4) | 5, 6, 8, 9 |
| 8 | 85.2, C | - | - | 86.6, C | - | - |
| 9 | 37.8, CH2 | 1.50 m; 2.53 dd (12.9, 3.3) | 8, 10, 11 | 35.4, CH2 | 1.6 t (12.9); 2.81 dd (12.9, 3.3) | 8, 10, 11 |
| 10 | 55.8, CH | 4.00, m | 9 | 60.1, CH | 4.82, m | - |
| 11 | 30.9, CH2 | 1.74, m; 2.32, m | - | 30.5, CH2 | 2.06, m; 2.68, m | 12, 13 |
| 12 | 28.5, CH2 | 2.06, m; 2.25, m | 10, 11,13 | 31.4, CH2 | 3.38, m | 10, 11,13 |
| 13 | 54.9, CH | 4.21, m | 12, 14, 22 | 160.7, C | - | - |
| 14 | 54.1, CH | 2.68, d (4.7) | 13, 15, 16, 22 | 123.6, C | - | - |
| 15 | 82.8, C | - | - | 86.6, C | - | - |
| 16 | 32.8, CH2 | 1.27, m; 1.68, m | - | 37.4, CH2 | 3.01–3.08, br m | 14, 17, 18, 22 |
| 17 | 19.8, CH2 | 1.80, m; 1.87, m | 15, 16 | 25.1, CH2 | 1.80, m; 1.87, m | 16, 22 |
| 18 | 34.5, CH2 | 1.48, br m | - | 39.5, CH2 | 1.48, br m | - |
| 19 | 67.8, CH | 3.81, m | 17, 18 | 68.0, CH | 3.74, m | 17 |
| 20 | 22.1, CH3 | 1.08, d (6.2) | 18, 19 | 21.9, CH3 | 1.14, d (6.2) | 18, 19 |
| 21 | 150.8, C | - | - | 151.3, C | - | - |
| 22 | 175.1, C | - | - | 179.5, C | - | - |
Figure 4COSY and key HMBC correlations for compounds 3 to 5.
Figure 5Structures of batzelladine C.
1H NMR (500 MHz) and 13C NMR (125 MHz) Data for crambescin B 281 (4) and crambescin B 253 (5) in CD3OD.
| 4 | 5 | |||||
|---|---|---|---|---|---|---|
| position | δC, type | δH, mult, | HMBC | δC, type | δH, mult, | HMBC |
| 1 | 154.4, C | - | - | 154.4, C | - | - |
| 2 | 88.0, C | - | - | 88.0, C | - | - |
| 3 | 67.3, CH2 | 3.86, 3.98; dd (12.8, 6.5) | 2, 4 | 67.3, CH2 | 3.86, 3.98; dd (12.8, 6.5) | 2, 4 |
| 4 | 54.7, CH2 | 1.97, 2.22; m | - | 54.7, CH2 | 1.97, 2.22; m | - |
| 5 | 36.8, CH2 | 1.91, 2.14; m | 2, 4 | 36.8, CH2 | 1.91, 2.14; m | 2, 4 |
| 6 | 37.7, CH2 | 1.62, 1.93; m | 2, 7, 8, 9 | 37.7, CH2 | 1.62, 1.93; m | 2, 7, 8, 9 |
| 7 | 47.1, CH | 3.59; m | - | 47.1, CH | 3.59; m | - |
| 8 | 34.9, CH2 | 1.49, 1.63; m | 7 | 34.9, CH2 | 1.49, 1.63; m | 7 |
| 9 | 25.1, CH2 | 1.22–1.14; m | - | 25.1, CH2 | 1.22–1.13; m | - |
| 10 | 29.5, CH2 | 1.22–1.14; m | 29.4, CH2 | 1.22–1.13; m | - | |
| 11 | 29.5, CH2 | 1.22–1.14; m | 29.2, CH2 | 1.22–1.13; m | - | |
| 12 | 29.4, CH2 | 1.22–1.14; m | - | 38.1, CH2 | 1.22–1.13; m | - |
| 13 | 29.3, CH2 | 1.22–1.14; m | - | 22.9, CH2 | 1.22–1.13; m | - |
| 14 | 38.1, CH2 | 1.22–1.14; m | - | 14.1, CH3 | 0.87; t (7.1) | 12, 13 |
| 15 | 22.9, CH2 | 1.22–1.14; m | - | |||
| 16 | 14.1, CH3 | 0.87; t (7.1) | 14, 15 | |||
Scheme 1Structure of crambescin B and hypothetic biosynthesis of 4 or 5.
Figure 6Drawing of Somartex®. (A) trapping module, (B) submersible pump, (C) cover dome, (D) Somartex platform, (E) water circulation inside the module. The water is forced to pass through the trapping material (ex. XAD resin) present in the (F) compartment, through the holed tube. The water can then reach the second module through the holed grid, (G) superposition of different modules that may contain different means of molecular trapping.